drug combination
199 articles
A New Approach to MEK Inhibition for First-Line Treatment
Dr. Eileen O’Reilly outlines a phase III trial of a targeted therapy for patients with metastatic pancreatic cancer.
Noninvasive Surgery and a New Drug to Stop Pancreatic Tumors
A clinical trial combines irreversible electroporation (IRE) and immunotherapy to see if the duo is effective against locally advanced pancreatic cancer.
Safety and Effectiveness of a New Drug for Advanced Pancreatic Cancer
Researchers are testing dose safety and effectiveness of a new drug for pancreatic cancer, in combination with gemcitabine.
Multicenter Trial Focuses on Neoadjuvant Treatment for Borderline Resectable and Locally Advanced Disease
Dr. David Ryan outlines a new trial for pre-surgical pancreatic cancer treatment combining a blood pressure drug, immunotherapy, standard care and SBRT.
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
Highlights from the 2025 AACR Annual Meeting
Drugs to target KRAS, better imaging for earlier detection, and cachexia prediction are among the research highlights from AACR 2025.
Immunotherapy to Enhance Standard Chemotherapy for Advanced Pancreatic Cancer
Researchers are testing an immunotherapy drug approved for other advanced cancers for effectiveness against pancreatic cancer.
Taking a Look At FAK Inhibitors
Dr. Conan Kinsey is looking at how FAK inhibitors can make immunotherapy more effective in combination with chemotherapy.
A New Combination Targeting the RAS Pathway
Researchers are testing two new drugs that target the RAS pathway, to make standard chemotherapy more effective.
Testing the Safety of an Immunotherapy Combination After Surgery
A new clinical trial tests the safety of a monoclonal antibody and personalized cancer vaccine plus chemotherapy after surgery to remove pancreatic cancer.
Targeting the Oxidation Pathway to Treat Advanced Pancreatic Cancer
Researchers are testing a new drug that targets the oxidation pathway in order to make standard chemotherapy more effective for stage IV pancreatic cancer.
Drug Onivyde Gives New Hope to Patients with Advanced Pancreatic Cancer
Onivyde (injectable irinotecan), combined with fluorouracil and leucovorin, has been approved as a second-line treatment for advanced pancreatic cancer.
AACR Virtual Special Conference on Pancreatic Cancer: Day Two Highlights
Let’s Win and the Lustgarten Foundation present highlights of Day Two of the AACR Virtual Special Conference on Pancreatic Cancer.
Chemotherapy Plus Minimally Invasive Surgery for Pancreatic Cancer
Researchers want to know if irreversible electroporation (IRE) makes it easier for chemotherapy to reach pancreatic cancer cells.
Researching More Second-Line Options for Pancreatic Cancer
Dr. Allyson Ocean explains the concept behind a novel second-line treatment being tested for metastatic pancreatic cancer.